Status: Recruiting
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Participants needed: 86
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: A2A Pharmaceuticals Inc.Updated: Jun 18, 2026Locations: 6
Eligibility criteria
Adults ≥ 18 years of age. [+26]
Patients with symptomatic brain metastases requiring treatment and/or leptomenin... [+8]